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Background: Angelman syndrome is a monogenic neurologic disorder that affects 1 in 15,000 children, and is
characterized by ataxia, intellectual disability, speech impairment, sleep disorders, and seizures. The disorder is
caused by loss of central nervous system expression of UBE3A, a gene encoding a ubiquitin ligase. Current
treatments focus on the management of symptoms, as there have not been therapies to treat the underlying
molecular cause of the disease. However, this outlook is evolving with advances in molecular therapies, including
artificial transcription factors a class of engineered DNA-binding proteins that have the potential to target a specific
site in the genome.
Results: Here we review the recent progress and prospect of targeted gene expression therapies. Three main issues
that must be addressed to advance toward human clinical trials are specificity, toxicity, and delivery.
Conclusions: Artificial transcription factors have the potential to address these concerns on a level that meets and
in some cases exceeds current small molecule therapies. We examine the possibilities of such approaches in the
context of Angelman syndrome, as a template for other single-gene, neurologic disorders.
Keywords: Artificial transcription factor, Engineered zinc finger, TALE, CRISPR, Gene regulation, Gene therapy,
Blood–brain barrier, Angelman syndrome, Autism spectrum disordersReview
Angelman syndrome is a neurodevelopmental disorder
that affects 1 in 15,000 children [1]. The disease is char-
acterized as an autism spectrum disorder with individ-
uals exhibiting severe mental and physical impairments,
including a lack of speech and ataxia. In a normal indi-
vidual, the region encoding the gene UBE3A is epigenet-
ically imprinted throughout neuronal brain cells, with
the maternal allele being preferentially expressed and
the paternal allele silenced [2]. In Angelman syndrome,
expression of the active maternal allele is lost [3]. Loss
of the maternal allele, while the paternal allele remains
silenced, results in a lack of UBE3A expression. Appro-
ximately 70% of all cases involve a large, 5–7-Mb, de-
novo maternal deletion of the chromosome 15q11-q13
region, which includes the critical UBE3A gene [2]. The* Correspondence: djsegal@ucdavis.edu
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article, unless otherwise stated.remaining known causes of Angelman syndrome involve
mutations within UBE3A (~11%), uniparental disomy
(~7%), and imprinting defects (~3%) [4]. About 10% of
cases present phenotypically as Angelman syndrome but
with currently unknown genetic or epigenetic causes. A
gradient of severity affecting both motor function and
cognitive ability is exhibited among Angelman syndrome
individuals, correlating roughly with the size of the dele-
tion. Individuals with point mutations tend to have less
severe symptoms. There are no curative treatments for
Angelman syndrome. Current treatments focus on be-
havioral and physical therapies to minimize symptoms.
Drug therapies are used to control seizures and sleep
disruption. However, the lack of potential therapies is
rapidly changing as advances in molecular therapy that
focus on altering a specific genes expression approach
human clinical trials [5,6].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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restoring UBE3A expression
For gene therapy to be a viable treatment option it is es-
sential that the genetic target is known, and that there is
evidence that a postnatal intervention would be bene-
ficial. In 1997 mutations in UBE3A or that severely re-
duced expression of the maternal copy of UBE3A were
found to be the causative for Angleman syndrome [3,7,8].
UBE3A is one of the many E3 ubiquitin ligases, which are
known to add chains of ubiquitin to specific proteins and
thus target them for proteasome degradation. A simple
model for Angelman syndrome is that lack of UBE3A in-
creases the concentration or persistence of its target pro-
teins. However, more complex models would also need to
consider that some E3 ligases facilitate monoubiquitina-
tion, which is associated with signaling rather than deg-
radation, as well as evidence that UBE3A can act as a
transcriptional co-regulator [9]. In 2011, a potential role
for Ube3a in mouse neuronal synapse firing and long-
term potentiation (LTP) was suggested by the discovery of
its interactions with Arc and Ephexin 5. Arc was shown to
be over-expressed in the absence of Ube3a, causing a de-
pletion of AMPA receptors at the synapse and thus de-
fects in synaptic plasticity, the chemical basis of learning
and memory [10]. Also, the degradation of Ephexin5 was
found to be mediated by Ube3a, which promoted aberrant
excitatory synapse development [11]. More recently, loss
of UBe3a was found to affect the cytoskeletal protein
actin, providing an explanation for the known defects in
dendritic spine density, LTP and learning [12]. However,
there are likely many other targets and potential functions
of UBE3A. Designing interventions to only one target or
activity might produce only a partial benefit, and compre-
hensive therapy of all downstream effectors might be im-
practical. A more attractive therapeutic approach would
be amelioration of the upstream causative event; that is,
restoration of UBE3A expression.
The developmental delay of Angelman syndrome gener-
ally becomes noticeable after 6 to 12 months of age. Since
the brain has been without UBE3A expression throughout
development, an important consideration is whether late-
stage (postnatal) intervention might have clinical value.
The first study supporting that it could was based on the
observation that αCaM kinase II was inhibited by phos-
phorylation in a mouse model of Angelman syndrome
[13]. Substitutions that prevented the inhibition rescued
many of the phenotypes of Angelman mice, suggesting
that the major lesion was signaling and not abnormal de-
velopment. Since αCaM kinase II is predominantly ex-
pressed postnatally [14,15], the study also suggested that
other postnatal interventions might have efficacy.
Since the underlying genetic defects are known, gene
therapy could, in principle, be applied to replace the
missing components. However, replacement of the entire5–7-Mb region that is deleted in the majority of
Angelman syndrome cases is not a viable option due
to size limitations imposed by most viral vectors [16]. A
pragmatic approach might be to replace just the causative
gene. In a mouse model of Angelman syndrome [17], hip-
pocampal injection of recombinant adeno-associated virus
serotype 9 (AAV9) carrying a cDNA of the mouse Ube3a
produced localized restoration of Ube3a to wild-type le-
vels [18]. The virus showed only modest distribution be-
yond the hippocampus, resulting in improvements in
associative learning and memory defects. However, motor
coordination deficits were not ameliorated by the treat-
ment, possibly due to the AAV9 not reaching the cerebel-
lum. Another concern of this approach is that the use of a
Ube3a cDNA could alter the balance of the three known
isoforms and result in only a partial functional restoration
[19,20]. The necessity of a wide distribution and multiple
isoforms of the gene is common in neurologic disorders,
where a treatment with only a single localized cDNA dis-
tribution may not be sufficient for a full phenotypic
rescue. The AAV study showed that a partial rescue was
possible by postnatal introduction of a Ube3a cDNA, fur-
ther supporting that the developmental changes may be
reversible using late-stage interventions. This initial AAV
study also encouraged the exploration of less traditional
methods that could be translated to humans.
An attractive alternative approach for Angelman syn-
drome is the reactivation of the intact but silent paternal
copy of UBE3A that exists in almost all affected individ-
uals. Paternal UBE3A is epigenetically silenced not by pro-
moter DNA methylation but by a long antisense RNA
transcript referred to as the UBE3A-ATS (Figure 1). This
600-kb transcript initiates at the paternal SNURF and
SURPN genes, extends through several clusters of small
nucleolar RNAs including the SNORD116 cluster, and
continues through the paternal open reading frame of
UBE3A [21]. This transcript is not expressed on the ma-
ternal allele, allowing expression of the maternal UBE3A.
Although the exact mechanism of inhibition is still being
elucidated, it is verified that the expression of UBE3A-ATS
on the paternal allele severely reduces expression of the
otherwise active paternal UBE3A [21-23].
Progress toward reactivating the paternal allele was
made in a drug screen, which utilized mice that were
transgenic for a Ube3a-yellow fluorescent protein fu-
sion on the silenced paternal allele [20]. The screen
showed reactivation of paternal Ube3a was possible
through use of topoisomerase inhibitors such as topotecan
[24]. Topotecan was shown to work by inhibiting tran-
scriptional progression of the Ube3a-ATS, resulting in
expression of paternal Ube3a. The drug was found to
stabilize R-loop formation in the upstream Snord116
cluster, resulting in extending chromatin decondensa-
tion but reduced transcriptional progression through
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Figure 1 Epigenetically imprinted genes at the Angelman locus. The region of 15q11-13 shown is approximately that of the most common
5-Mb deletion. On the paternal allele, the green genes are expressed but the red genes are not. On the maternal allele, the imprint is reversed,
green genes expressed, and red genes are not. Genes shown in blue are active on both the paternal and maternal chromosomes. Colored arrows
indicate the direction of active transcription. The 600-kb brain-specific UBE3A-ATS transcript (indicated by black arrow) silences the paternal copy
of UBE3A. Deletion of the maternal region therefore results in loss of UBE3A expression in the brain.
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by confirming that reactivation of paternal Ube3a was
possible by therapeutic targeting of the Ube3a-ATS tran-
script. The result was especially promising since topotecan
was an FDA-approved anti-cancer drug. The value of re-
purposing FDA-approved drugs is particularly important
for rare diseases, as it is often felt that the cost of develop-
ing a new drug and bringing it successfully through full
clinical trials would be financially unrealistic with the lim-
ited resources available for rare disease research. However,
various complications involving specificity, toxicity, bio-
distribution, and delivery have impeded the advance of
topoisomerase inhibitors toward human trials for Angel-
man syndrome treatment.
The concept that reduced Ube3a-ATS expression would
increase paternal Ube3a expression was further supported
by a recent study using a mouse model that contained a
transcriptional termination signal inserted in the Ube3a-
ATS gene [22]. The insertion of the poly(A) cassette in the
Ube3a-ATS gene resulted in premature termination of
Ube3a-ATS transcript, allowing Ube3a transcription to
proceed without inhibition. The increased paternal Ube3a
expression did not reach full wild type levels, but the par-
tial increase significantly affected phenotype. The study
explored the concept of the extent to which paternal
Ube3a expression could compensate for maternal Ube3a
loss if the compensation was present from birth. Sig-
nificant improvements were observed in obesity, LTP,
long-term memory, and a variety of motor skills. These
findings suggest that partial expression of paternal Ube3a
is sufficient to ameliorate several of the phenotypes as-
sociated with Angelman syndrome in mice. This mouse
model was created from a single genetically modified cell,
thus the same method could not be used for therapy in
humans.Characteristics of an ideal therapy
An ideal therapy would be specific to the targeted gene
(e.g., UBE3A), exhibit low toxicity over a long period,
and be deliverable by minimally invasive means. Speci-
ficity remains one of the most common and problemati-
cal issues facing potential molecular treatment. A lack of
specificity is common among small molecules that work
on a DNA level. For example, chromatin-modifying agents
such as 5-azaC and SAHA affect DNA methylation and
histone acetylation globally, rather than targeting a spe-
cific gene [27]. Topotecan was shown to affect the tran-
scription of over 150 long genes in human neuronal
cultures [25]. As the length of the size of the genes be-
came longer than 67 kb, inhibition of transcription in-
creased. The regulation of “off-target” genes could lead to
unwanted side effects and toxicity. As with all treatment
strategies, optimization of dosage and timing of treatment
can be examined for possible reduction of side effects.
The issue of specificity is not unique to drugs and remains
a concern for “biologics” and other molecular therapies.
Another issue is the delivery of the therapeutic agent
to the site of action. The delivery problem is compoun-
ded when the desired target is the entire brain and the
therapeutic agent must cross the blood brain barrier or
be delivered by intracranial injection [18,24,28]. Often,
direct intracranial injection will only affect a small por-
tion of the brain. Imprinting of UBE3A and the 15q11-
q13 region has been shown to occur throughout the
brain [20,29]; therefore, the limited distribution of a drug
might not be sufficient for effective therapeutic outcome.
Even with multiple injections and ideal spread through-
out the brain, the degradation of transient therapeutic
molecules would eventually require additional intracranial
injections. One way to circumvent multiple injections
would be to deliver a viral vector that would express the
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Figure 2 DNA-binding platforms for artificial transcription
factors. (a) Each repeat module of an engineered zinc finger
protein recognizes three base pairs of DNA. The VP64 transcriptional
activation domain is shown in cyan. Other common effector
domains include the KRAB repression domain. (b) Each repeat of a
TALEN protein recognizes one base pair of DNA. A thymine base
(red) just 5′ of the repeat-bound DNA site is preferred for high-
affinity binding. (c) An engineered CRISPR system consists of a guide
RNA (red strand with colored sections) that directs the Cas9 nuclease
(light blue) to the target DNA. Mutation of the two-endonuclease
domains (arrows with red X) produces a non-catalytic DNA-binding
domain, to which an effector domain can be attached. The required
protospacer adjacent motif (PAM), NGG, is shown 3′ to the target site.
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delivery of both cDNA of Ube3a [18] and shRNAs to
topoisomerase 1 and 2 [25] in mice. AAV and integration-
defective lentiviral vectors deliver non-integrating epi-
somes that are stable and can provide nearly indefinitely
expression in the non-dividing neurons [30]. However, the
restricted packaging capacity of AAV limits its therapeutic
application to the delivery of small cDNAs or nucleic
acids. Antibodies against AAV also limit their use in
humans [31]. Perhaps the largest limitation is that viral
distribution is largely restricted to area around the in-
jected region [28,32]. Viral vectors with wider distribu-
tion would be useful for fostering long-term expression
throughout the brain, as would likely be the case for
Angelman syndrome.
The potential of engineered DNA-binding proteins for
therapy
For a disease caused by a single gene, the possibility of
targeted gene therapy has started to gain momentum
[33]. Though over 1800 gene therapy trails have been ini-
tiated since 2000, few have focused on autism spectrum
disorders [34]. Angelman syndrome is one of several neu-
rologic disorders that are caused by a single gene mu-
tation, making it an ideal candidate for gene expression
therapy. The ability to engineer DNA-binding proteins
has enabled the possibility for therapeutic regulation
of endogenous genes [35-38]. Such engineered DNA-
binding proteins include C2H2 zinc fingers, transcrip-
tion activator-like effectors (TALEs), and clustered regularly
interspaced short palindromic repeat (CRISPR) systems
(Figure 2). These factors can be programmed to act as
activators or repressors for specific gene expression by
attaching transcriptional or epigenetic effector domains,
creating artificial transcription factors (ATFs) [39-42]. In
the context of Angelman syndrome, such ATFs could be
used to reactivate the paternal UBE3A that is silenced by
imprinting, or inactivate the paternal UBE3A-ATS anti-
sense transcript. For Prader-Willi syndrome, caused by a
deletion of the paternal segment of 15q11-13, ATFs could
activate the silenced maternal UBE3A-ATS with the goal
of restoring the critical SNORD116 transcripts that are
spliced from UBE3A-ATS [43]. In Dup15q syndrome,
caused by a segmental duplication of 15q11-13, ATFs
could repress maternal UBE3A to reduce the doubled ex-
pression [44]. In Pitt-Hopkins syndrome, ATFs could in-
crease expression of wild type TCF4 in cases of TCF4
haploinsufficiency [45]. In Rett syndrome, caused by mu-
tation in one copy of MECP2 on the X-chromosome,
ATFs could activate the epigenetically silenced wild-
type allele on the other X-chromosome in females [46].
Zinc finger and TALE-based ATFs achieve targeting
specificity using amino acid side chains that recognize
particular DNA base pairs through hydrogen bondingand Van der Waals interactions. A single zinc finger
module is able to recognize approximately three base
pairs of DNA. Considerable protein engineering efforts
were able to generate modules or sets of co-evolved
modules that could be assembled together to target a
wide spectrum of DNA sequences [47-51]. TALEs were
originally characterized from Xanthomonas bacteria
[40,41] and contain a series of repeat modules. Each re-
peat uses two amino acids to recognize one base pair of
DNA. The TALE repeats can be assembled in any order
necessary to target a genomic site. The spectrum of se-
quences that can be targeted by TALEs is more versatile
then that of zinc fingers. However, TALEs do not yet
have the extensive animal testing and validation history
of zinc fingers. No human clinical trials have been re-
ported using TALEs, making their performance and tox-
icity in humans unknown.
In 2012, a new and powerful methodology called
CRISPR emerged on the gene manipulation landscape
[52]. This system utilizes a large protein, Cas9, which is
targeted to a specific site in the genome by a guide RNA
(gRNA) to create an RNA-directed double-stranded DNA
nuclease. CRISPR systems are found in many archea and
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bacteriophages and plasmids. The endonuclease activity
can be inactivated by mutation and transcriptional effector
domains attached to create RNA-directed ATFs [42]. This
technology offers the most flexibility and expedient de-
sign of ATFs. Retargeting requires only the insertion of
a new 20-nt recognition sequence in the gRNA, which
can be synthesized in a time and cost efficient manner.
CRISPR technology has been used successfully in nu-
merous cell culture experiments, and the simultaneous
regulation of multiple genes has been shown using Cas9
and multiple gRNAs encoded on a viral vector [38].
CRISPR technology is still in its infancy and many tests
need to be conducted on the specificity and toxicity before
initiating a human clinical trial. The current power of
CRISPR resides in rapid synthesis of multiple ATFs and
the potential to regulate multiple genes in cell or animal
models.Challenges of utilizing DNA-binding proteins as
therapeutics
One of the largest concerns for ATF-based therapy is
off-target effects. It should be noted that concerns about
off-target activities of ATFs are somewhat less than for
nucleases; ATFs would likely have effects in only the 10-
20% of the genome that contains regulatory elements
[53], whereas nucleases have the potential to create mu-
tations and rearrangements in 100% of the genome. Off-
target effects have been shown to occur at variable rates
for different targeting platforms. The off-target binding
sites can be predicted to a large extent from in vitro and
in vivo assays, making it possible to screen ATF candi-
dates and select the most specific ones before human tri-
als. For example, Bind-n-Seq and SELEX are methods to
evaluate the most favored in vitro binding sites of an
ATF from a random pool of all possible DNA targets
[54]. Off-target sites can be predicted in silico based on
similarity to the on-target site, then interrogated directly
by analysis of epigenetic modification (if an appropriate
epigenetic modification domain was used) [55] or chro-
matin immunoprecipitation [56]. Perhaps, the most ro-
bust in vivo methodology for evaluating off target
binding is chromatin immunoprecipitation analyzed by
high throughput sequencing (ChIP-Seq) [57]. Surpris-
ingly, only a few studies to date have examined off-
target effects by changes in non-target RNA and protein
expression e.g., [58]. An ideal in-depth analysis of off-
target events would involve genome wide screening for
off-target binding sites by ChIP-Seq, coupled with ana-
lysis of potential off-target gene regulation by RNA-Seq
and proteomics. The potential for specific on-target
regulation and direct measurement of off-target effects
allows for optimization of prospective therapeutic ATFs,making this approach an attractive long-term gene re-
gulation option for clinical use.
Another important concern for all interventions is tox-
icity of the treatment. To date, the only ATF that has
been introduced into humans is a zinc finger-based fac-
tor that increased VEGF expression, which progressed
through Phase I and II clinical trials [6]. A total of 280
juvenile patients received the therapy and reported min-
imal adverse side effects. The ATF was delivered as a
DNA plasmid injected intramuscularly. Unfortunately,
little improvement was observed in patients. Efficacy
aside, the clinical trials demonstrated that zinc finger
ATFs were well tolerated by patients over an extended
time. This tolerance, particularly the apparent lack of
immune response, may have been expected since zinc
fingers comprise one of the largest protein families in
humans [59]. In contrast, there have been no reports yet
examining the immune response of bacteria-originating
TALEs or Cas9 in humans.
A significant obstacle to be overcome for every poten-
tial therapy is delivery of the therapeutic to the desired
organ. As discussed above, the brain presents a unique
challenge due to the blood brain barrier. Methods cap-
able of crossing the blood brain barrier include liposo-
mal delivery, cell penetrating peptides (CPPs), and small
molecule drugs that are hydrophobic or capable of bind-
ing transcytosis proteins [60]. ATFs have been delivered
to organisms through viral injections, purified protein,
CPP-attached protein, and as naked coding DNA [35,36].
A potential advantage that ATFs have when delivered by a
viral vector is that a protein can be coded to have a secre-
tion and re-uptake domain, dramatically increasing its po-
tential spread through the brain, overcoming the obstacle
that cDNA vectors have of only localized viral spread
[24,30]. Extensive studies have not been conducted to
evaluate the potential of brain delivery of ATFs, but it is
possible that one or several of these methods could prove
successful.
Conclusions
The advances that have taken place in Angelman syn-
drome research in the last twenty years have made it an
ideal candidate for targeted molecular therapy. Recent
advances have verified an intact but silenced paternal
UBE3A. The paternal allele has been re-activated in mice
by small molecule drugs that inhibit the transcription
of Ube3a-ATS, however these drugs had several off-
target effects and delivery limitations. In principle, ATFs
may offer several advantages for specificity and delivery.
ATFs have advanced in recent years, enabling regulation of
specific gene transcripts in the human genome [58]. The
delivery mechanisms of ATFs are still being optimized,
but several options hold promise for crossing the blood
brain barrier and long-term, gene-specific regulation.
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Angelman syndrome, allowing for the expression of
paternal UBE3A and perhaps a full phenotypic rescue. A
similar approach could be applied to other monogenetic
neurologic disorders, and potentially even multi-gene
disorders.
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